DakoCytomation signs agreement on novel prostate cancer markers
P504S is a tumor specific marker and P501S is specific for prostate tissue.
"These new antibodies will allow us to strengthen our portfolio of products for managing patients with prostate cancer", said Dennis Chenoweth, Corporate Vice President of Diagnostics for DakoCytomation. "Our goal continues to be optimizing care for patients with all types of cancer."
DakoCytomation will use Corixa's antibodies to develop tests for diagnostic use. The eventual goal is to expand the company's portfolio of diagnostic tests for managing patients with prostate cancer and to help physicians link diagnostic assay results to specific therapies and treatment outcomes.
Prostate cancer is the most common non-skin cancer found in men and the second leading cause of cancer deaths in men. The World Health Organization estimates some 250,000 new cases of prostate and testicular cancer are diagnosed globally each year.
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.